Skip to main content

Empowering precision drug development

Clinicogenomics data offer a new frontier for insights about potential treatments, target populations and safety profiles.

What Clinicogenomics Means for Drug Development

Experts from Optum, UnitedHealth Group and Merck discuss clinicogenomics and new insights for potential treatments, target populations and safety profiles. Explore how linking phenotypic and genomic or other -omic data helps to assess the full view of the patient journey.

Learn more about Optum Clinicogenomics.

Visit the Optum Life Sciences home page.

Fuel your next discovery

Streamline the drug research and development process through discovery of high-value biomarkers, the genetic landscape and barriers to access.

Related content

Clinicogenomics: new, linked data is advancing research

Rich, longitudinal clinicogenomics data can fuel all stages of drug development.

DNA, Personalized Medicine and…Zebras?

Nearly 30 million Americans live with a rare disease. Hear how genomics are shaping how we treat everything from ultra-rare diseases to the most prevalent cancers.

The 11 things life sciences leaders need to know

We identified 11 trends worth watching.